MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC

BACKGROUND: ROS1 tyrosine kinase inhibitors (TKIs) have demonstrated significant clinical benefit for ROS1+ NSCLC patients. However, TKI resistance inevitably develops through ROS1 kinase domain (KD) modification or another kinase driving bypass signaling. While multiple TKIs have been designed to t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tyler, Logan C., Le, Anh T., Chen, Nan, Nijmeh, Hala, Bao, Liming, Wilson, Timothy R., Chen, David, Simmons, Brian, Turner, Kristen M., Perusse, Dean, Kasibhatla, Shailaja, Christiansen, Jason, Dudek, Arkadiusz Z., Doebele, Robert C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626307/
https://www.ncbi.nlm.nih.gov/pubmed/36101520
http://dx.doi.org/10.1111/1759-7714.14656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626307/
https://www.ncbi.nlm.nih.gov/pubmed/36101520
http://dx.doi.org/10.1111/1759-7714.14656

Ejemplares similares